Incidental Pulmonary Nodule

Definition

• Pulmonary nodule: a well-defined lesion ≤30 mm that is completely surrounded by lung parenchyma. A lesion >30 mm is a mass and is far more likely to be malignant.
• Incidental nodule: a nodule found on imaging done for an unrelated reason, such as abdominal CT, trauma CT or CT angiography for PE.
• The standard incidental-nodule pathway assumes an asymptomatic patient ≥35 years old with general-population lung cancer risk.

Morphology (drives every later decision)

• Solid: dense, homogeneous soft tissue. This is the most common type.
• Subsolid: vessels and airways remain visible through the lesion. There are two subtypes:
• Pure ground-glass nodule (GGN): no solid component.
• Part-solid nodule: has both ground-glass and solid components. It carries the highest malignancy likelihood of the three types.

Why it matters

• The single clinical question is the probability of malignancy.
• Early-stage lung cancer resected at the nodule stage has a five-year survival of roughly 70–80%.
• Over-investigation of benign nodules adds procedural complications, radiation and cost.
• Management therefore balances curing early cancer against harming patients with benign lesions.

Epidemiology

• Most incidental nodules are benign. In the Pan-Canadian and British Columbia screening cohorts of high-risk smokers, only about 1% of more than 12,000 nodules were malignant.
• The malignant fraction is lower still in average-risk patients.
• Subsolid nodules are being found more often because CT use is rising and adenocarcinoma incidence is increasing.

Populations that need a different pathway

• Screening-detected nodules, managed with the ACR Lung-RADS system.
• Immunocompromised patients, in whom infection is favored.
• Patients with known active malignancy.
• Symptomatic patients, who follow the suspected lung cancer workup.
• Multiple nodules: evaluation targets the dominant or most suspicious lesion.

Malignant causes

• Primary lung cancer:
• Adenocarcinoma is the most common malignant nodule (about 50%) and is typically peripheral.
• Squamous cell carcinoma accounts for 20–25% and is usually central.
• Large cell carcinoma is also peripheral.
• Primary pulmonary lymphoma and sarcoma are rare.
• Metastases: melanoma, sarcoma, and carcinomas of the bronchus, colon, breast, kidney and testis. In a patient with known extrathoracic cancer, a new nodule on chest radiograph is metastatic about 25% of the time.
• Carcinoid: usually endobronchial, but about 20% present as a peripheral, smooth nodule.

Benign causes

• Infectious granuloma: accounts for about 80% of benign nodules.
• Histoplasma, Coccidioides, TB and nontuberculous mycobacteria are the main causes.
• S. aureus abscess can form a nodule that may cavitate.
• Dirofilaria (dog heartworm) causes a nonspecific peripheral nodule that mimics cancer.
• Hamartoma: accounts for about 10% of benign nodules. It presents in middle age and grows slowly.
• Other benign tumors: fibroma, leiomyoma, hemangioma and pneumocytoma. None has distinguishing imaging features.
• Vascular:
• Pulmonary AVM, classically in hereditary hemorrhagic telangiectasia.
• Infarct, pulmonary varix and hematoma.
• Inflammatory: granulomatosis with polyangiitis, rheumatoid nodule, sarcoidosis and amyloidoma.
• Other: rounded atelectasis, intrapulmonary lymph node and bronchogenic cyst.
• Pseudo-nodules: fissural fluid (pseudotumor), mucoid impaction and nipple shadow.

Risk factors for malignancy, non-modifiable

• Age: malignant fraction by age band is roughly 3% at 35–39, 15% at 40–49, 43% at 50–59 and >50% at ≥60.
• Female sex, family history of lung cancer and prior malignancy.
• Emphysema.

Risk factors for malignancy, modifiable

• Smoking: the dominant risk factor, highest in current smokers. Risk falls with years since quitting.
• Asbestos exposure.

Nodule factors favoring malignancy

• Larger size, upper-lobe location, spiculation, part-solid attenuation and fewer nodules.

Favors infection

• Immunocompromise.
• Multiple nodules.
• Residence in an endemic fungal region.

Why benign lesions look benign

• Healed granuloma: a contained infection undergoes caseous necrosis and then dystrophic calcification. This produces the reassuring central, diffuse or lamellated calcification patterns, classically from Histoplasma or TB.
• Hamartoma: a disorganized mix of cartilage, fat, smooth muscle and myxoid tissue.
• Calcifying cartilage produces popcorn (chondroid) calcification, although this is seen in fewer than 10% of hamartomas.
• Macroscopic fat (−40 to −120 HU) within a smooth nodule is virtually diagnostic.
• Perifissural nodules: triangular or lentiform nodules on a fissure, usually intrapulmonary lymph nodes. In the Brock cohort, none of these was malignant.

Why malignant lesions look malignant

• Spiculation (corona radiata, sunburst sign): tumor cells infiltrate along the pulmonary interstitium.
• Lobulation: different parts of the tumor grow at different rates.
• Caveat: up to 20% of lung cancers and many metastases have smooth margins. Margin shape alone cannot exclude cancer.

Why ground glass means adenocarcinoma

• The adenocarcinoma spectrum runs from atypical adenomatous hyperplasia to adenocarcinoma in situ to minimally invasive to invasive adenocarcinoma.
• Early lesions grow along alveolar walls (lepidic growth) and leave air in the alveoli. This produces ground-glass attenuation.
• An invasive component fills the airspace and appears as a new or enlarging solid component, the signal that the lesion is progressing.

Growth kinetics

• Most cancers have a volume doubling time (VDT) of 20–400 days.
• A nodule that doubles in <20 days is too fast for cancer and suggests infection.
• A solid nodule that is stable for >2 years is likely benign.
• Exceptions with slow VDT (>400 days): typical carcinoid and adenocarcinoma in situ or minimally invasive adenocarcinoma.
• Median VDT by attenuation in one study was about 813 days for ground-glass, 457 days for part-solid and 149 days for solid cancers. This is why subsolid nodules need 5 years of follow-up.

Why FDG-PET fails in predictable ways

• FDG marks glycolytic activity, which is present in both tumor and inflammation.
• False positives: infection, granulomas and sarcoidosis.
• False negatives: low-metabolism tumors (carcinoid, adenocarcinoma in situ, minimally invasive and mucinous adenocarcinoma) and hyperglycemia, in which serum glucose competes with FDG uptake.
• Resolution limit: PET cannot reliably assess nodules or solid components under about 8 mm.

Classic scenario

• Asymptomatic by definition. The typical stem is a patient in their 50s–60s, often a current or former smoker, whose CT for abdominal pain, trauma or suspected PE shows a lung nodule.
• Physical exam is usually normal. Findings should prompt a search for a systemic cause rather than reassurance.

Stem clues that point to a specific cause

• Endemic fungi: residence in the Ohio or Mississippi River valley or the Midwest suggests Histoplasma; the desert Southwest suggests Coccidioides. A calcified granuloma is then most likely.
• FDG-PET is also less specific in these regions.
• HHT features: recurrent epistaxis, mucocutaneous telangiectasias and a family history, with a nodule that has a feeding artery and draining vein, indicate a pulmonary AVM.
• Right-to-left shunting through the AVM can cause hypoxemia or paradoxical embolic events.
• Systemic disease:
• Rheumatoid arthritis suggests a rheumatoid nodule.
• Sinusitis, hematuria and positive ANCA suggest granulomatosis with polyangiitis.
• Hilar adenopathy with erythema nodosum suggests sarcoidosis.
• Known extrathoracic cancer (melanoma, sarcoma, renal, colon, breast, testicular): a new nodule may be metastatic.
• Immunocompromise: favors infection, so the interval to repeat imaging is shortened.
• Fever and cough with an infiltrate-like nodule suggest pneumonia. Treat, then repeat the radiograph in 6–8 weeks to document resolution.

Findings that take the patient off the incidental pathway

• Hemoptysis, weight loss, new cough, hoarseness or bone pain. These move the patient to the suspected lung cancer workup, with staging and tissue diagnosis.
• Associated mediastinal lymphadenopathy, consolidation or a mass on the dedicated chest CT also redirects the workup.

Chest radiograph pitfalls

• Nipple shadow: seen on up to 11% of frontal films and typically bilateral and symmetric. Repeat the film with nipple markers rather than ordering CT.
• Small nodules: most nodules under 1 cm are not visible on plain film, so a normal radiograph does not exclude a nodule.

Step 1: find old imaging.

• Comparing with any prior images is the single best first step.
• Growth favors malignancy, and long-term stability favors a benign cause.

Step 2: dedicated chest CT.

• Obtain a non-contrast, low-dose, thin-section (<1.5 mm) volumetric CT.
• This applies whenever the nodule was seen on a chest radiograph, MRI, PET or an incomplete CT (neck, abdomen or spine).
• Size is recorded as the average of the long and short axes.

Findings that end the workup as benign

• Macroscopic fat, which indicates a hamartoma.
• Benign calcification: central, diffuse, lamellated or popcorn.
• Punctate, eccentric or amorphous calcification is indeterminate.
• Metastatic osteosarcoma or chondrosarcoma can calcify.
• Stability: ≥2 years for a solid nodule or ≥5 years for a subsolid nodule on CT.
• Two-year stability on chest radiograph is unreliable, with a positive predictive value for benignity of only about 65%.

Growth criteria

• Solid nodule: an increase of >2 mm in average diameter.
• Subsolid nodule: increasing attenuation, or a new or enlarging solid component.

Step 3: estimate pretest probability for indeterminate nodules.

• Risk categories are low (<5%), intermediate (5–65%) and high (>65%).
• Approximate malignancy rates by size: <5 mm under 1%, 5–9 mm about 2–6%, 8–20 mm about 18%, >20 mm over 50%.
• Validated models combine clinical and imaging features:
• The Brock (PanCan) model is the only one that includes attenuation, but it was derived in smokers.
• The Mayo Clinic model uses age, smoking, cancer history, diameter, spiculation and upper-lobe location.
• The VA model was derived in veterans who smoked.
• These models add the most value for nodules of 8–30 mm.

Step 4: FDG-PET/CT for solid nodules >8 mm at intermediate risk.

• Pooled sensitivity is about 89% and specificity about 75%.
• An SUV >2.5 is commonly used as the threshold for suspicion.
• PET is not useful for ground-glass nodules, where sensitivity and specificity were reported as roughly 10% and 20%.
• It is also not useful for solid components ≤8 mm.
• PET additionally stages disease and identifies the safest biopsy target.

Step 5: tissue diagnosis.

• CT-guided transthoracic needle biopsy (TTNB): suited to peripheral nodules. Sensitivity for malignancy is >90%, even under 1 cm, and core biopsy is preferred over fine-needle aspiration.
• Bronchoscopy:
• Conventional bronchoscopy works best for large, central lesions.
• Radial EBUS and navigational or robotic bronchoscopy extend reach to the periphery with less pneumothorax risk.
• Nondiagnostic results: 15–30% of TTNB samples are nonspecific or nondiagnostic, and up to 46% of these later prove malignant.
• VATS wedge resection is the gold standard for diagnosis.

Any growing or FDG-avid nodule

• Proceed to tissue diagnosis.

Solid nodule <6 mm

• No routine follow-up.
• A CT at 12 months is optional if risk factors are present, since cancer risk is well under 1%.

Solid nodule 6–8 mm

• CT at 6–12 months.
• Repeat at 18–24 months if the patient is high risk or stability is uncertain.
• Do not order PET or needle biopsy at this size, because neither is reliable.

Solid nodule >8 mm

• Low probability: CT at 3 months, then at 9–12 and 18–24 months.
• Intermediate probability: FDG-PET/CT and/or biopsy.
• An avid nodule should be biopsied or excised.
• If PET is negative or indeterminate, individualize with a low threshold for biopsy.
• Serial CT is an acceptable alternative.
• High probability: biopsy or surgical excision, with PET/CT for staging.

Pure ground-glass nodule

• <6 mm: no follow-up.
• ≥6 mm: CT at 6–12 months, then every 2 years to 5 years. Many resolve because they are inflammatory.
• Growth or a new solid component calls for tissue diagnosis.

Part-solid nodule

• <6 mm: no follow-up.
• ≥6 mm: CT at 3–6 months. If the nodule persists, the next step depends on the solid component:
• Solid component >8 mm: PET/CT, then biopsy or resection.
• Solid component ≤8 mm: annual CT for 5 years.

Multiple nodules

• Repeat CT at 3–6 months, or sooner if immunocompromised, since most are infectious or inflammatory.
• Manage persistent nodules by the most suspicious one.

Surgical definitive management

• The sequence is a VATS wedge resection, then frozen section.
• If non-small cell lung cancer is confirmed, convert to lobectomy with mediastinal node sampling in the same operation. Segmentectomy is used when lung function is limited.

Screening-detected nodules

• Manage with ACR Lung-RADS, not the incidental algorithm.
• USPSTF screening criteria: age 50–80, ≥20 pack-years, and currently smoking or quit within 15 years.

Avoid

• Biopsy of a suspected AVM.
• PET or needle biopsy for nodules ≤8 mm or pure ground-glass nodules.
• Follow-up by chest radiograph.

Complications of the nodule itself

• Delayed or missed cancer: an under-investigated malignant nodule can progress past the curable stage.
• One retrospective study found a modestly higher proportion of stage III–IV disease with less intensive evaluation.
• Delays of up to about 8 months may still carry a favorable prognosis in early-stage disease.
• Pulmonary AVM:
• Right-to-left shunting can cause paradoxical embolic stroke or brain abscess.
• Rupture can cause hemorrhage.

Complications of transthoracic needle biopsy

• Pneumothorax: the most common complication, occurring in 10–17% of procedures. About half of these need a chest tube, roughly 7% of all TTNBs.
• Mechanism: the needle breaches the visceral pleura.
• Risk rises with emphysema or COPD, crossing a fissure, traversing more than two pleural surfaces, a deep lesion, age over 60 and smoking.
• Signal: new dyspnea or chest pain after the procedure.
• Tension pneumothorax is an emergency.
• Pulmonary hemorrhage or hemoptysis: clinically apparent in about 1–9.5% of cases. It is common on post-biopsy CT, but intervention is rarely needed.
• Risk factors: dual antiplatelet therapy (aspirin plus clopidogrel) is the major one. Cutting needles, small ground-glass targets and deep lesions also increase risk.
• Systemic air embolism: rare, at 0.2–0.5%, but potentially fatal.
• Mechanism: air enters the pulmonary veins and travels to the systemic arteries.
• Signal: sudden neurologic deficit or cardiac ischemia during or after the procedure.
• This is an emergency.
• Needle-tract tumor seeding: rare.

Complications of surgery

• Frozen-section error: frozen section is unreliable for lesions under about 1.1 cm and for carcinoid, adenocarcinoma in situ, minimally invasive adenocarcinoma and atypical adenomatous hyperplasia. Missed NSCLC may need a second operation, a completion lobectomy.
• Operative mortality: low with VATS, but rises with underlying lung disease.
• Benign resections: aggressive strategies remove benign nodules without clear benefit.

Complications of surveillance

• Cumulative radiation: modest with modern low-dose CT, which delivers about 1.5 mSv per scan.
• New nodules: about 10% of patients develop new nodules per year of follow-up, and each needs its own assessment.
• Anxiety and cost from repeated imaging.

• Best next step for any new nodule: obtain prior imaging for comparison. If the nodule was seen on a chest radiograph, order a non-contrast thin-section chest CT, not a repeat radiograph.
• ***Popcorn* calcification or fat (−40 to −120 HU) means hamartoma.**
• Central, diffuse or lamellated calcification indicates a healed granuloma, from Histoplasma or TB.
• Eccentric or punctate calcification is indeterminate.
• Stability rule: 2 years for solid and 5 years for subsolid nodules on CT.
• Subsolid nodules need longer because adenocarcinoma in situ and minimally invasive adenocarcinoma double slowly.
• A nodule that doubles in under 20 days is infection, not cancer.
• Size thresholds under the Fleischner Society guidelines:
• <6 mm solid: no follow-up.
• 6–8 mm: CT at 6–12 months.
• >8 mm: risk-stratify with CT at 3 months, PET/CT, or tissue sampling.
• PET traps:
• False negatives: carcinoid, adenocarcinoma in situ or mucinous adenocarcinoma, ground-glass nodules, nodules under 8 mm and hyperglycemia.
• False positives: granulomas, TB and sarcoidosis. Specificity is lower in endemic fungal regions.
• Features favoring cancer: spiculation (corona radiata), upper-lobe location, a part-solid nodule, older age and smoking.
• A smooth margin does not exclude cancer.
• Perifissural nodules are benign lymph nodes.
• Feeding artery plus draining vein means AVM (HHT). Do not biopsy.
• Distractors to avoid:
• A nondiagnostic needle biopsy does not mean benign.
• Screening-detected nodules follow ACR Lung-RADS, not the incidental algorithm.
• Adenocarcinoma is peripheral, whereas squamous cell carcinoma is central.